The obizur market research report is one of a series of new reports that provides obizur market statistics, including obizur industry global market size, regional shares, competitors with a obizur market share, detailed obizur market segments, market trends and opportunities, and any further data you may need to thrive in the obizur industry. This obizur market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to increasing aging population prone to rare bleeding disorders, rising global healthcare spending, growing funding for bleeding disorder research, increasing healthcare access in emerging economies, rising prevalence of chronic conditions. Major trends in the forecast period include advancements in recombinant protein therapies, technological improvements in drug delivery systems, development of next-generation factor viii formulations, development of ai-based tools for diagnosing and managing hemophilia, innovations in biomanufacturing processes for recombinant therapies.
The growing number of hemophilia A cases is expected to drive the expansion of the Obizur market. Hemophilia A is a genetic disorder caused by a deficiency or malfunction of clotting factor VIII, resulting in prolonged bleeding. As life expectancy improves with better medical care and diagnostic tools, more cases of hemophilia A are being identified and managed, leading to an increase in the condition's prevalence. Obizur is essential for treating hemophilia A as it provides a recombinant form of factor VIII, which is deficient in affected individuals. This helps restore normal blood clotting, especially in cases of acquired hemophilia A, where the immune system produces inhibitors against natural factor VIII. For example, in November 2023, the National Library of Medicine reported that, as of July 2022, 10,276 individuals with hemophilia were enrolled from 87 treatment centers across 40 countries. Nearly half of these patients (49%) had severe hemophilia, with 99% being male, 85% having hemophilia A, and 67% coming from low- and middle-income countries. This growing prevalence of hemophilia A is expected to propel the Obizur market.
The increasing healthcare expenditure is expected to further stimulate the growth of the Obizur market. Healthcare spending encompasses all financial resources allocated to medical services, treatments, pharmaceuticals, hospital care, and other health-related services. Rising healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, and increased demand for healthcare services. This trend positively impacts Obizur, as higher healthcare spending improves access to advanced treatments for rare conditions such as acquired hemophilia A, thus driving greater demand for therapies such as Obizur. Additionally, increased funding for healthcare research and development fosters innovation, which supports the creation of new treatments and expands market opportunities. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in healthcare expenditure in the UK between 2022 and 2023, compared to just 0.9% growth the year before. This rising healthcare expenditure is contributing to the growth of the Obizur market.
An important trend in the Obizur market is the expansion of facilities dedicated to biopharmaceutical research and development. Facility expansion involves increasing the size, capacity, or capabilities of existing biopharmaceutical facilities to meet growing demand, enhance operations, or support new activities. For example, in September 2023, Takeda Pharmaceutical Company, based in Japan, opened a new research and development lab in the Donaustadt district of Vienna. The company is making a significant investment in a biopharmaceutical R&D facility in the Seestadt Aspern region of Vienna, its largest investment in Austria, where it has operated for nearly 70 years. This new facility, expected to employ around 250 researchers by 2026, will focus on developing innovative therapies for diseases with unmet needs and will be built to the highest ecological standards.
The companies operating in the obizur market are Baxter International Inc, and Takeda Pharmaceutical Company Limited.
North America was the largest region in the obizur market in 2024. The regions covered in obizur report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the obizur market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Obizur is the brand name for susoctocog alfa, a medication used to treat bleeding episodes in individuals with hemophilia A who have developed inhibitors (antibodies) to standard treatments such as factor VIII. Obizur is a recombinant human coagulation factor VIII, designed to replace the deficient or absent factor VIII in people with hemophilia A, helping to control bleeding and promote clotting.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Obizur is primarily indicated for congenital hemophilia A with inhibitors, acquired hemophilia A, and other bleeding disorders. Congenital hemophilia A with inhibitors is a genetic condition in which patients lack clotting factor VIII and develop inhibitors that target factor VIII replacement therapies. Obizur is available in both lyophilized powder and intravenous solution forms and is distributed through various channels, including wholesalers, distributors, and online pharmacies. It is commonly used in hospitals, specialty clinics, and home care settings.
The obizur market consists of sales of coagulation factor concentrates, factor replacement therapy kits, antibody inhibitor treatments and infusion systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing aging population prone to rare bleeding disorders, rising global healthcare spending, growing funding for bleeding disorder research, increasing healthcare access in emerging economies, rising prevalence of chronic conditions. Major trends in the forecast period include advancements in recombinant protein therapies, technological improvements in drug delivery systems, development of next-generation factor viii formulations, development of ai-based tools for diagnosing and managing hemophilia, innovations in biomanufacturing processes for recombinant therapies.
The growing number of hemophilia A cases is expected to drive the expansion of the Obizur market. Hemophilia A is a genetic disorder caused by a deficiency or malfunction of clotting factor VIII, resulting in prolonged bleeding. As life expectancy improves with better medical care and diagnostic tools, more cases of hemophilia A are being identified and managed, leading to an increase in the condition's prevalence. Obizur is essential for treating hemophilia A as it provides a recombinant form of factor VIII, which is deficient in affected individuals. This helps restore normal blood clotting, especially in cases of acquired hemophilia A, where the immune system produces inhibitors against natural factor VIII. For example, in November 2023, the National Library of Medicine reported that, as of July 2022, 10,276 individuals with hemophilia were enrolled from 87 treatment centers across 40 countries. Nearly half of these patients (49%) had severe hemophilia, with 99% being male, 85% having hemophilia A, and 67% coming from low- and middle-income countries. This growing prevalence of hemophilia A is expected to propel the Obizur market.
The increasing healthcare expenditure is expected to further stimulate the growth of the Obizur market. Healthcare spending encompasses all financial resources allocated to medical services, treatments, pharmaceuticals, hospital care, and other health-related services. Rising healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, and increased demand for healthcare services. This trend positively impacts Obizur, as higher healthcare spending improves access to advanced treatments for rare conditions such as acquired hemophilia A, thus driving greater demand for therapies such as Obizur. Additionally, increased funding for healthcare research and development fosters innovation, which supports the creation of new treatments and expands market opportunities. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in healthcare expenditure in the UK between 2022 and 2023, compared to just 0.9% growth the year before. This rising healthcare expenditure is contributing to the growth of the Obizur market.
An important trend in the Obizur market is the expansion of facilities dedicated to biopharmaceutical research and development. Facility expansion involves increasing the size, capacity, or capabilities of existing biopharmaceutical facilities to meet growing demand, enhance operations, or support new activities. For example, in September 2023, Takeda Pharmaceutical Company, based in Japan, opened a new research and development lab in the Donaustadt district of Vienna. The company is making a significant investment in a biopharmaceutical R&D facility in the Seestadt Aspern region of Vienna, its largest investment in Austria, where it has operated for nearly 70 years. This new facility, expected to employ around 250 researchers by 2026, will focus on developing innovative therapies for diseases with unmet needs and will be built to the highest ecological standards.
The companies operating in the obizur market are Baxter International Inc, and Takeda Pharmaceutical Company Limited.
North America was the largest region in the obizur market in 2024. The regions covered in obizur report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the obizur market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Obizur is the brand name for susoctocog alfa, a medication used to treat bleeding episodes in individuals with hemophilia A who have developed inhibitors (antibodies) to standard treatments such as factor VIII. Obizur is a recombinant human coagulation factor VIII, designed to replace the deficient or absent factor VIII in people with hemophilia A, helping to control bleeding and promote clotting.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Obizur is primarily indicated for congenital hemophilia A with inhibitors, acquired hemophilia A, and other bleeding disorders. Congenital hemophilia A with inhibitors is a genetic condition in which patients lack clotting factor VIII and develop inhibitors that target factor VIII replacement therapies. Obizur is available in both lyophilized powder and intravenous solution forms and is distributed through various channels, including wholesalers, distributors, and online pharmacies. It is commonly used in hospitals, specialty clinics, and home care settings.
The obizur market consists of sales of coagulation factor concentrates, factor replacement therapy kits, antibody inhibitor treatments and infusion systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Obizur Market Characteristics4. Obizur Market Trends And Strategies5. Obizur Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Obizur Pricing Analysis & Forecasts30. Global Obizur Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Obizur Market32. Recent Developments In The Obizur Market
3. Obizur Market Biologic Drug Characteristics
6. Global Obizur Growth Analysis And Strategic Analysis Framework
8. Obizur Market Segmentation
9. Global Obizur Epidemiology Of Clinical Indications
10. Obizur Market Regional And Country Analysis
11. Asia-Pacific Obizur Market
12. China Obizur Market
13. India Obizur Market
14. Japan Obizur Market
15. Australia Obizur Market
16. South Korea Obizur Market
17. Western Europe Obizur Market
18. UK Obizur Market
19. Germany Obizur Market
20. France Obizur Market
21. Eastern Europe Obizur Market
22. North America Obizur Market
23. USA Obizur Market
24. Canada Obizur Market
25. South America Obizur Market
26. Middle East Obizur Market
27. Africa Obizur Market
28. Obizur Market Competitive Landscape And Company Profiles
29. Global Obizur Market Pipeline Analysis
33. Obizur Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Obizur Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on obizur market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for obizur ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The obizur market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Congenital Hemophilia A with Inhibitors; Acquired Hemophilia A; Other Bleeding Disorders2) By Formulation: Lyophilized Powder; Intravenous Solution
3) By Distribution Channel: Wholesalers Or Distributors; Online Pharmacies
4) By End User: Hospitals; Specialty Clinics; Home Care Settings
Key Companies Profiled: Baxter International Inc; Takeda Pharmaceutical Company Limited
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Baxter International Inc
- Takeda Pharmaceutical Company Limited